Antibiotic Policy Solutions An Ocean Apart Between U.S., EU
This article was originally published in The Pink Sheet Daily
Governments are taking on different initiatives to solve the problem of developing products to address worries about drug-resistant bacteria. The EU is helping to fund trials, while the U.S. is offer extended exclusivity.
You may also be interested in...
Cubist Sets Sights On European Antibiotics Market With Zurich Move: A Conversation With Patrick Vink
Cubist recently has seen its key antibiotic Cubicin become a blockbuster in the U.S. It is determined to take this success, backed by a flourishing pipeline, to answer Europe's call for products to fight antimicrobial resistance.
At the annual anti-infectives meeting, experts consider revamping the business model to spur development of novel antibiotics, with cooperation of regulators in Europe and U.S.
Congress should allow the agency to determine which drug-resistant bacteria sponsors should target in order to earn incentives for antibiotic development, rather than list specific pathogens, CDER Director Janet Woodcock suggested to a House panel March 8. The window to change the GAIN Act appears to be closing, though.